Navigation Links
Isogen Launches Major New Facility to Address Global Biopharma Demand
Date:11/19/2008

NEWARK, Del., Nov. 19 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, today announced the first phase launch of its contract facility in Delaware. Isogen was founded to specifically address the process, facility and capacity problems commonly associated with the $2 billion highly-niched, low-volume clinical and early-stage commercial sterile filling market segment.

Companies can invest over $100 million and four years to develop sterile manufacturing capacity, but are highly reluctant to take this initiative until they are certain the candidate drug will receive regulatory approval. Isogen's Phase I facility will accommodate GMP vial and syringe filling, ranging in fill size up to 4,000 units per shift in fully segregated, isolator-based fill lines in a potent capable facility. Isolator-based lyophilization capacity is planned for later in 2009. The January 21st facility launch sets a new industry standard for GMP compliant clinical manufacturing and containment, enabling Isogen's customers to plan and execute the supply of integrated sterile clinical and small scale commercial launches of single or multiple therapeutics at the same time while dramatically reducing costs and risks that are inherently associated with other in-house and outsourced alternatives.

"Isogen's facility launch will help our customers address major industry dynamics that are reshaping the face and complexity of sterile clinical trials materials supply," said Les Edwards, CEO, Isogen. "Regulators in the U.S. and Europe increasingly require sterile clinical trials supplies to be manufactured in accordance with current Good Manufacturing Practice (cGMP) standards. At the same time many new pipeline drugs moving into clinical trials require Isogen's unique barrier isolation containment technology. Our process ensures safe manufacturing, while meeting strict global regulatory standards," Edwards concluded.

Isogen will offer an integrated GMP clinical and early commercial contract filling service comprising sterile process development, analytical laboratory services and pharmaceutical engineering consulting. Isogen's Advanced Sterile Filling offers full product segregation and isolator-based sterile processing. The facility meets global regulatory standards and operates according to cGMP. Isogen's industry subject matter experts and a combination of its analytical pharmaceutical laboratory and engineering service functions make Isogen a fully integrated Contract Development and Manufacturing Organization (CDMO) capable of supporting client contract from formulation to distribution.

About Isogen

Isogen is the leader in advanced sterile manufacturing for potent and non-potent therapeutics for the critical clinical/commercial scale manufacturing transition. Isogen provides a fully integrated suite of services including formulation, technology transfer and validation services for the contract filling of liquids and lyophilized formulations for vaccines, monoclonal antibodies and other synthetic and biologically derived therapeutics. Isogen delivers critical full service resources to pharmaceutical and biopharmaceutical manufacturers seeking solutions in advanced sterile filling including clinical and transitional contract filling, formulation/validation based analytical laboratory services and advanced sterile fill line/equipment design and GMP project management. For more information, contact Joe Romano, Partner, HighGround at +1-781-939-5800 x 208 or jromano@highgroundinc.com


'/>"/>
SOURCE Isogen
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
2. Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
5. Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center
6. Coapt Systems Launches FDA Cleared Novielle Voice (TM) for Restoration of Voice Loss
7. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
8. Agendia Launches TargetPrint(R) for Breast Cancer Patients
9. Aon eSolutions Launches Clinical Trials Module
10. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
11. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2020)... ... July 07, 2020 , ... With ... Navajo Nation residents, the 33 nonprofits who received the latest ISA Foundation ... round of funding, the foundation awarded grants totaling $838,527 to the U.S.-based 501(c)(3) ...
(Date:7/4/2020)... , ... July 03, 2020 , ... By Heidi Jean ... we’ve retreated into our homes for cover, Assuaged, Inc. is going full ... all over the globe this year to get their feet wet in marketing, social ...
(Date:7/2/2020)... ... July 02, 2020 , ... Realty ONE Group ... health series on its live agent Town Halls, furthering its commitment to its ... series includes special guests and Realty ONE Group leadership discussing social, mental, physical ...
Breaking Medicine Technology:
(Date:7/2/2020)... ... July 02, 2020 , ... Temprian, ... of autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients develop progressive ... , While vitiligo is equally prevalent in all ethnic groups, it ...
(Date:7/2/2020)... SHELTON, Conn. (PRWEB) , ... July 02, 2020 ... ... closure of many businesses, including dental offices for non-emergency work. In conjunction with ... released reopening guidelines for Connecticut dental practices in mid-May. , Due to ...
(Date:7/1/2020)... ... July 01, 2020 , ... The Society to Improve Diagnosis ... at the University of Massachusetts Medical School- Baystate and Ann Gaffey, RN, MSN, ... Board of Directors. Dr. Salvador and Ms. Gaffey’s service began in May and ...
(Date:6/28/2020)... ... , ... PathAI, a global provider of artificial intelligence (AI)-powered technology for use ... of PD-L1 expression to assess response in patients treated with Bristol Myers Squibb’s PD-1 ... Cancer Research (AACR) Annual Meeting. AACR was held June 22 to June 24. , ...
(Date:6/28/2020)... , ... June 27, 2020 , ... ... Classroom, the first online, full-day educational conference in the organization’s history. The online ... facioscapulohumeral muscular dystrophy (FSHD), which was cancelled this year due to COVID-19. Nearly ...
Breaking Medicine News(10 mins):